|
|
Article: Neurocrine Biosciences Announces Second Presentation of Indiplon Data at The American Psychiatric Association (APA) Meeting May 17-22; Results Demonstrate Latency to Persistent Sleep Was Significantly Improved In Subjects Receiving Indiplon Versus Placebo.
- Article from:
- PR Newswire
- Article date:
- May 22, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Neurocrine Biosciences, Inc. announced today that Neurocrine and Clinical Investigators from the Company's indiplon clinical development program presented an abstract reporting data from a Phase II clinical trial with indiplon at the upcoming American Psychiatric Association (APA) Meeting in San Francisco, May 17-22, 2003.
The abstract presented today, Thursday, May 22, 2003 explores the dose-related efficacy and tolerability of indiplon in healthy adults subjected to a well-accepted laboratory model of transient insomnia using objective polysomnography (PSG) assessments. This was a randomized, placebo-controlled, parallel group, dose-response Phase II clinical ...